An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemiaWalter Fiedler, Hubert Serve, Wolfgang E. Berdel et al.|Leukemia Research|2009Cited by 42
Cediranib targeting of circulating VEGFR-1+ monocyte subpopulationsHua Wu, John V. Heymach, Amado J. Zurita et al.|Journal of Clinical Oncology|2008Cited by 1